 | | Vol. 11.15 – 19 April, 2023 |
| |
|
|
| To enhance T cell immunity across epitopes infrequently altered in SARS-CoV-2 variants, the authors designed BNT162b4, an mRNA vaccine component intended to be combined with BNT162b2, the spike-protein-encoding vaccine.
[Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators described DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that elicited potent and durable neutralizing antisera in non-human primates against known variants of concern.
[Nature Communications] |
|
|
|
| Researchers demonstrated nearly complete escape of XBB.1.5, CH.1.1, and CA.3.1 variants from neutralizing antibodies stimulated by three doses of mRNA vaccine or by BA.4/5 wave infection, but neutralization was rescued by a BA.5-containing bivalent booster.
[Cell Reports] |
|
|
|
| Scientists injected mice with cocktails of rodent equivalents of human cytokine storms resulting from SARS-CoV-2/COVID-19 or Rhinovirus common cold infection.
[JCI Insight] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| To delineate mechanisms behind age-dependent susceptibility, investigators compared age-specific mouse models of invasive Streptococcus pneumoniae infection.
[Immunity] |
|
|
|
| The authors compared urothelial stem cell lines isolated from mice with a history of either resolved or chronic uropathogenic Escherichia coli infection, elucidating evidence of molecular imprinting that involved epigenetic changes.
[Nature Microbiology] |
|
|
|
| Using a mouse model of genital herpes simplex virus 2 (HSV-2) infection, scientists showed that interleukin-18 acted upon natural killer (NK) cells to promote accumulation of the serine protease granzyme B, coinciding with epithelial ulceration.
[Cell Reports] |
|
|
|
| Researchers have built a model of the “worst-case” failure from an improved understanding of the steps at which NS1 acted in the viral life cycle to prevent the triggering of an innate immune response.
[PLOS Pathogens] |
|
|
|
|
Scientists found that Pholiota squarrosa lectin, a lectin that specifically binds core fucose, bound to hepatitis B virus (HBV) particles and inhibited HBV infection of a modified human HepG2 cell line that expresses an HBV receptor.
[Scientific Reports] |
|  | |
|
|
| The authors highlight how understanding the interactions between intestinal helminths, microbiota, and their mammalian host at a cellular and molecular level can guide future treatment approaches.
[Cell Host & Microbe] |
|
|
|
|
| SAB Biotherapeutics announced that the US FDA has granted Breakthrough Therapy Designation to SAB-176, an investigational therapeutic, for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.
[SAB Biotherapeutics] |
|
|
|
|
| June 2 – 6, 2023
Chicago, Illinois, United States |
|
|
|
|
|
| | National Institutes of Health – Bethesda, Maryland, United States |
|
|
|
| | The University of Chicago – Chicago, Illinois, United States |
|
|
|
| | Sandia National Laboratories – Livermore, California, United States |
|
|
|
| | National Health Research Institutes – Zhunan, Taiwan |
|
|
|
| | The Beckman Research Institute of City of Hope – Duarte, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
